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Fusion oncogenes are prevalent in several pediatric cancers, yet little is known about the 68 
specific associations between age and phenotype. We observed that fusion oncogenes, like 69 
ETO2-GLIS2, are associated with acute megakaryoblastic or other myeloid leukemia subtypes 70 
in an age-dependent manner. Analysis of a novel inducible transgenic mouse model showed 71 
that ETO2-GLIS2 expression in fetal hematopoietic stem cells induced rapid megakaryoblastic 72 
leukemia while expression in adult bone marrow hematopoietic stem cells resulted in a shift 73 
toward myeloid transformation with a strikingly delayed in vivo leukemogenic potential. 74 
Chromatin accessibility and single cell transcriptome analyses indicate ontogeny-dependent 75 
intrinsic and ETO2-GLIS2-induced differences in key transcription factor activities, including 76 
ERG, SPI1, GATA1 and CEBPA. Importantly, switching off the fusion oncogene restored 77 
terminal differentiation of the leukemic blasts. Together, these data show that aggressiveness 78 
and phenotypes in pediatric acute myeloid leukemia result from an ontogeny-related 79 




This work demonstrates that the clinical phenotype of pediatric acute myeloid leukemia is 84 
determined by ontogeny-dependent susceptibility for transformation by oncogenic fusion 85 
genes. The phenotype is maintained by potentially reversible alteration of key transcription 86 
factors indicating that targeting of the fusions may overcome the differentiation blockage and 87 





Increasing evidences support a correlation between age, driver oncogene and disease 91 
phenotype in pediatric cancers (1,2). The differences between adult and pediatric cancers may 92 
stem from either the distinct properties of the driver oncogenes or inherent differences between 93 
fetal and adult tissue. In acute leukemia, some fusions oncogenes are acquired in utero and 94 
are diagnosed almost exclusively during childhood (3–5) for which efficient leukemogenesis 95 
models are lacking (6). Childhood de novo acute megakaryoblastic leukemia (AMKL) is an 96 
aggressive subtype of acute myeloid leukemia (AML) that harbors recurrent fusion oncogenes 97 
(e.g. ETO2-GLIS2, OTT-MAL, NUP98-KDM5A)(7–10). Intriguingly, several AMKL fusions are 98 
also detected in patients with other AML subtypes (8,11,12), although the determinants of the 99 
genotype/phenotype association remain unknown. Similarly to other aggressive childhood 100 
cancers such as Ewing sarcoma (13), these fusions are rarely associated with additional 101 
recurrent mutations in patients (9,14) and they strongly impact the epigenome (15,16), thereby 102 
suggesting that global transcriptional deregulation is sufficient to drive the disease and a likely 103 
candidate for direct therapeutic targeting (17,18). Nevertheless, these cancers currently lack 104 
adequate animal models that precisely recapitulate the characteristics of the disease observed 105 
in patients. Such models could provide mechanistic insights to understand pediatric cancer 106 
specificity. 107 
 108 
Several differences between fetal and adult normal hematopoiesis exist (19,20). In adults, 109 
hematopoietic stem cells (HSC) are at the top of a hierarchy and differentiate toward more 110 
committed progenitors to generate the mature blood cell types. Although the precise 111 
trajectories that govern normal hematopoiesis remain a matter of debate (21–24), 112 
leukemogenic processes are strongly influenced by the type of cell targeted by fusion 113 
oncogenes (25). A recent study has proposed that fetal liver (FL) hematopoiesis primarily 114 
involves multipotent progenitors, while adult hematopoiesis is chiefly regulated by committed 115 
progenitors with more restricted lineage potentials (26). This view is largely supported by single 116 
cell transcriptome data showing that most adult hematopoietic progenitors present signs of 117 
lineage commitment (27–29,24,21). At the molecular level, fetal and adult hematopoiesis 118 
present differential activity of LIN28B (30–33), GATA factors-regulated Polycomb complexes 119 
(34) and CEBPA/MYCN transcription factors (35). 120 
 121 
To better understand the genotype/phenotype association in pediatric cancers, we 122 
investigated how the fetal and adult cellular architectures (22–24,36,27) impact the 123 
transformation and disease phenotype driven by ETO2-GLIS2 (hereafter abbreviated EG). We 124 
developed an inducible transgenic mouse model that efficiently phenocopied the human 125 
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disease with striking differences in latency, phenotype and molecular wiring, depending on the 126 




AMKL is diagnosed at a younger age than AML in pediatric patients 131 
We first screened a cohort of 276 pediatric leukemia patients (37) for the presence of EG and 132 
confirmed that EG occurred in AMKL patients and other AML (AML-M0 to AML-M5) subtypes 133 
(12), with an overall incidence of 4.7% (Fig. 1A, B, Supplementary Table S1). The overall 134 
survival was poor for all patients with a trend towards a worse prognosis for those presenting 135 
with an AMKL phenotype (Supplementary Fig. S1A). In addition to the known EG+ MO7e 136 
megakaryoblastic cell line, we found that the CMS leukemia cell line was also EG+ and 137 
presented with a myeloid phenotype (Supplementary Fig. S1B-E). Strikingly, EG+ AMKL 138 
patients were diagnosed at a significantly younger age of (1.66±0.18 years [n=33]) compared 139 
with other EG+ AML patients (8.53±1.73 years [n=15]; p<0.0001)(Fig. 1C). A similar trend was 140 
observed in AMKL patients carrying either NUP98-KDM5A (Fig. 1D) or MLL fusions (Fig. 1E) 141 
as well as for all AMKL patients regardless of the genetic subgroup (Fig. 1F). 142 
We applied patient-derived xenografts (PDX)(8) to expand EG+ AMKL and EG+ AML cells in 143 
immunodeficient mice. Overall, 3/5 EG+ AMKL and 2/8 EG+ AML transplants successfully 144 
engrafted (Supplementary Table S1). While AMKL xenografts generally expressed the 145 
megakaryoblastic marker CD41+ but not the myeloid marker CD15- (as observed for patient 146 
#13), AML blasts were CD15+CD41- (e.g. patient #7)(Fig. 1G). Interestingly, we identified a 147 
six-year-old EG+ patient (#5) diagnosed as AML-M2, who presented with immature blasts 148 
(CD34+CD15-CD41-) and two smaller cellular fractions (CD34+CD41+CD15- or CD34+CD41-149 
CD15+)(Fig. 1G). All cell populations presented with distinct morphologies (Fig. 1H,I) and 150 
expressed EG (Supplementary Fig. S1F). Upon injection of the three flow-purified cell 151 
populations into secondary recipients, only the immature CD34+CD41-CD15- cell population 152 
successfully engrafted into recipients (Fig. 1J) and regenerated the three populations (Fig. 1K), 153 
thereby indicating dual megakaryoblastic and myeloid differentiation.  154 
Together, these results show that pediatric AMKL occurs at a significantly younger age than 155 
other AML subtypes irrespective of the driver oncogene. Importantly, the dual 156 
megakaryoblastic/myeloid phenotype in the EG+ patient indicates that AMKL-associated fusion 157 
oncogenes can transform HSC or multipotent progenitors.    158 
 159 
ETO2-GLIS2 efficiently induces leukemia in mice  160 
To analyze the determinants of EG-driven leukemogenesis and the associated 161 
megakaryoblastic and myeloid phenotypes, we established a doxycycline (Dox)-regulated 162 
 
 6 
transgenic mouse model (Supplementary Fig. S2A). Hereby, EG expression is controlled by a 163 
reverse tetracycline-controlled transactivator (rtTA) integrated into the Rosa26 gene locus, and 164 
results in similar EG expression levels as observed in AMKL patient blasts (Supplementary 165 
Fig. S2B-C). To assess the consequences of EG expression, we continuously exposed double 166 
transgenic iEG:rtTA females (hereafter abbreviated iEG) to Dox (Dox+, Fig. 2A). Although most 167 
hematological parameters remained unchanged at six weeks post-induction (data not shown), 168 
iEG animals consistently presented with an abnormal bone marrow (BM) Lin-CD150-Kit+CD41+ 169 
cell population (Supplementary Fig. S2D) bearing a myeloid and megakaryoblastic clonogenic 170 
potential in methylcellulose cultures (Supplementary Fig. S2E). Later, Dox-treated iEG animals 171 
developed lethal hematological malignancies with a prevalence of 96.9% (31/32 mice, 172 
Supplementary Fig. S2F), which was classified into two groups based on the most abundant 173 
blast populations (Fig. 2B, C, Supplementary Fig. S2G). Approximately 20% of the mice (4/19, 174 
Group 1) presented with a CD41+ (megakaryoblastic) phenotype with a median latency of 164 175 
days (Fig. 2D). Group 2 presented with heterogenous phenotypes ranging from predominantly 176 
Kit+ (immature) with low number of CD11b+Gr1+ (myeloid) cells to predominantly maturing Kit-177 
CD11b+Gr1+ myeloid features after a median latency of 251 days (Fig. 2B-D, Supplementary 178 
Fig. S2G). Histological analyses revealed altered spleen architectures and confirmed that BM 179 
and spleens from Group 1 mice were infiltrated with immature von Willebrand factor (VWF+) 180 
megakaryoblasts, while Group 2 presented with myeloid features in the BM and extramedullary 181 
hematopoiesis in the spleen (Fig. 2C, Supplementary Fig. S2H). All diseased mice developed 182 
hepatosplenomegaly (Fig. 2E) and anemia (Fig. 2F) and Group 1 was associated with 183 
significantly higher white blood cell (WBC) counts (Fig. 2F). The cell-autonomous nature of the 184 
disease and its dependence on EG expression was demonstrated by transplantation of BM 185 
cells into Dox+ wild-type (WT) recipients that developed disease after a shorter mean latency 186 
(120 days), while Dox- recipients never developed any disease (Fig. 2G-J, Supplementary Fig. 187 
S2H). Collectively, this inducible transgenic model faithfully recapitulates EG+ leukemia 188 
development as observed in patients. 189 
 190 
Developmental stage determines the phenotype of ETO2-GLIS2+ leukemia  191 
To investigate the impact of the developmental stage, we induced iEG expression in Lin- 192 
hematopoietic stem and progenitor cells (HSPC) obtained from fetal liver (FL) at embryonic 193 
day (E) 12.5, newborn BM (1-2 weeks old) and adult BM (ABM, 8 weeks old) (Fig. 3A). In vitro, 194 
iEG expression significantly increased the clonogenic activity with passages in all contexts 195 
(Fig. 3B). While iEG+ FL-derived cells homogeneously expressed CD41, iEG+ ABM-derived 196 
cells also consistently showed a CD11b+Gr1+ myeloid phenotype (Fig. 3C, Supplementary Fig. 197 
S3A). Newborn-derived iEG cells presented with a myelo/megakaryoblastic intermediate 198 
phenotype between that of FL and ABM. Similar results were obtained upon retroviral 199 
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expression of EG in WT cells (Supplementary Fig. S3B). These data indicate that fetal 200 
hematopoiesis favors EG-induced megakaryoblastic transformation in vitro. 201 
To compare the capacity of FL- and ABM-derived iEG cells to develop disease, we 202 
transplanted 1x106 mononuclear iEG cells from E14.5 FL or ABM donors (carrying a 203 
ubiquitously-expressed GFP reporter to track their progeny) donors into Dox+ WT recipients 204 
(Fig. 3A). Mice engrafted with iEG FL cells developed lethal leukemia with median latency (39 205 
days)(Fig. 3D) characterized by splenomegaly, high WBC, anemia, thrombocytopenia, and 206 
infiltration with CD41+ megakaryoblasts in several organs, while mice engrafted with iEG ABM 207 
cells developed the disease after a significantly prolonged latency (median 397 days, 208 
p=0.0008) associated with heterogenous phenotypes ranging from Kit+CD41- immature to 209 
predominantly CD11b+Gr1+ myeloid features (Fig. 3D-H and data not shown). To address the 210 
consequences of EG expression on fetal progenitors in vivo, we exposed pregnant females 211 
(E13) to Dox and analyzed the embryos 36 hours later. All iEG-expressing embryos showed 212 
gross morphological and hematological abnormalities (Fig. 3I), with decreased erythroid and 213 
myeloid cells and increased megakaryoblastic progenitors (Fig. 3J). 214 
Taken together, these observations show that the developmental stage determines the 215 
predominance of aggressive megakaryoblastic over myeloid leukemia upon ETO2-GLIS2 216 
expression. 217 
 218 
ETO2-GLIS2 expression in fetal LT-HSC induces a megakaryoblastic phenotype  219 
To address the consequence of EG on distinct populations of the hematopoietic hierarchy, we 220 
purified control (CTRL) and iEG long-term HSC (LT-HSC) and multipotent progenitors (MPP2, 221 
MPP3 and MPP4)(38) obtained from E14.5 FL or ABM (Supplementary Fig. S3C) and 222 
characterized their clonogenic and phenotypic profile in Dox+ methylcellulose cultures (Fig 4A). 223 
CTRL FL LT-HSC and MPP generated both myeloid Gr1+ and megakaryoblastic CD41+ cells 224 
(Fig. 4B, Supplementary Fig. S3D), thereby confirming that most normal mouse FL progenitors 225 
maintain a megakaryoblastic potential as observed in humans (26). iEG FL LT-HSC and MPP2 226 
cells exclusively generated CD41+ cells (Fig. 4B, Supplementary Fig. S3D), MPP3 cells yielded 227 
a large majority of CD41+ cells and rare Gr1+ myeloid cells (Fig. 4B, Supplementary Fig. S3D), 228 
and MPP4 cells did not significantly form any colony (Supplementary Fig. S3E). iEG FL LT-229 
HSC and MPP2/3 cells showed increased replating activity compared with CTRL (Fig. 4C). To 230 
define the differentiation potential of iEG-transformed cells, iEG FL LT-HSC and MPP2/3 cells 231 
derived from the fourth plating were cultured without Dox (Fig. 4A), which resulted in myeloid 232 
and megakaryoblastic differentiation respectively (Fig. 4D, Supplementary Fig. S3F). CD41+ 233 
and Gr1+ iEG cell lines could be derived after flow purification and long-term cultures 234 
(Supplementary Fig. S3H) and their CD41+ megakaryoblastic phenotype correlated with the 235 
high presence of Dox (Supplementary Fig. S3I). Consistently, higher ETO2-GLIS2 expression 236 
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was observed in AMKL vs. AML patient blasts (Supplementary Fig. S1G), supporting the 237 
importance of EG dosage as shown for other fusion oncogenes (39). 238 
Using ABM cells, CTRL LT-HSC formed Gr1+ and CD41+ cells (Fig. 4E, F), whereas CTRL 239 
MPP2/3/4 cells generated almost exclusively Gr1+ cells (Fig. 4F, Supplementary Fig. S3D), 240 
indicating that the megakaryoblastic potential is qualitatively and quantitatively lower in ABM 241 
than in FL (Supplementary Fig. S3G). By contrast, iEG ABM LT-HSC gave rise almost 242 
exclusively to CD41+ cells, while MPP2/3/4 cells generated CD11b+Gr1+ myeloid cells with a 243 
higher proportion than iEG FL MPP (Fig. 4F, Supplementary Fig. S3D). While iEG FL MPP4 244 
cells did not generate colonies, iEG ABM MPP4 cells showed increasing clonogenic activity 245 
upon serial replatings and a myeloid morphology (Fig. 4F-H).  246 
We next investigated whether iEG endows single LT-HSC or MPP3 cells with dual 247 
myeloid/megakaryoblastic phenotypic potential as observed in patient #5 (Fig. 1G). The 248 
majority (56%) of CTRL ABM LT-HSC-derived cells showed a dual phenotype, while others 249 
showed either megakaryoblastic or myeloid phenotypes. Upon iEG induction, ABM LT-HSC 250 
formed primarily megakaryoblastic colonies (89%) with only a few dual phenotype colonies 251 
(11%)(Fig. 4I, J, Supplementary Fig. S3J). While CTRL MPP3 cells exclusively generated 252 
myeloid cells under these conditions, 48% of iEG MPP3 cells yielded a dual megakaryoblastic 253 
and myeloid profile, thereby indicating that EG imposes megakaryoblastic as well as dual 254 
myeloid/megakaryocytic potential on single MPP3 progenitors.  255 
Collectively, these data show that murine FL HSPC present a higher susceptibility to 256 
megakaryoblastic transformation by EG than ABM HSPC. They also demonstrate that EG 257 
expression in ABM LT-HSC results in an exclusively megakaryoblastic phenotype, while 258 
expression in further committed progenitors is required for myeloid transformation. 259 
 260 
ETO2-GLIS2 alters the LT-HSC transcriptional network in an ontogeny-dependent 261 
manner 262 
To compare the molecular consequences of EG expression in different developmental (FL vs. 263 
ABM LT-HSC) or hierarchical (LT-HSC vs. MPP4 ABM cells) contexts, we performed single 264 
cell RNAseq (scRNAseq) on these purified populations after a 24-hour Dox induction in CTRL 265 
and iEG cells. Clustering and differential expression analyses revealed that iEG impacted FL 266 
LT-HSC transcriptome more than those from ABM LT-HSC (3772 vs. 151 differentially-267 
expressed genes, respectively) or MPP4 (only 3 differentially-expressed genes) (Fig. 5A, 268 
Supplementary S4A-C, Supplementary Tables 2-4). Previously defined signatures of 269 
upregulated (“Up”) genes in ETO2-GLIS2+ AMKL patients (40,41) were enriched in iEG+ LT-270 
HSC derived from both FL and ABM contexts. However, the signature of downregulated 271 
(“Down”) genes in ETO2-GLIS2+ AMKL patients was only deregulated in FL LT-HSC (Fig. 5B, 272 
Supplementary Fig S4D). iEG MPP4 cells showed few differentially expressed genes and no 273 
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enrichment for EG+ AMKL patient signatures (Supplementary Fig. S4D). These data show that 274 
the iEG signature obtained in FL LT-HSC better recapitulates the molecular consequences 275 
observed in EG+ AMKL patients than the signatures observed in ABM LT-HSC or MPP4. 276 
GSEA showed enrichment of stem cell signatures in both fetal and adult iEG LT-HSC (e.g. 277 
Myct1, Esam), significantly more pronounced for several genes in fetal LT-HSC (e.g. Vwf and 278 
Hlf)(Fig. 5C, D, Supplementary Fig. S4E, F). Expression signatures from progenitors and more 279 
mature populations (e.g. MPP3, MPP4, Monocytes, Neutrophils, Megakaryocytes) were 280 
significantly downregulated in FL LT-HSC compared to adult LT-HSC with a lower expression 281 
of myeloid (e.g. Spi1), erythroid (e.g. Nfe2) and megakaryocytic genes (e.g. Mpl) (Fig. 5C, E, 282 
Supplementary Fig. S4E), supporting a more pronounced blockage of differentiation in FL LT-283 
HSC.  284 
To investigate related transcription factor (TF) activities, network inference and activity 285 
prediction with ARACNe and VIPER programs was used (Supplementary Fig. S5A, 286 
Supplementary Tables S5-7). This first confirmed a higher expression level and activity of EG 287 
in iEG+ cells on Dox (Supplementary Fig. S5B). For several key TF, it also predicted 288 
significantly different activities without significant difference in mRNA expression 289 
(Supplementary Fig. S5C, Supplementary Tables S8-9). Accordingly, activity-based clustering 290 
confirmed that iEG expression impacted adult LT-HSC more than MPP4 cells (Supplementary 291 
Fig. S5D). Several TFs know to act as oncogenes or cofactors (e.g. ERG, HLF, MECOM, 292 
HOXA10, MEIS1) presented increased activities, while other key differentiation TF were 293 
downregulated (RBM15, SPI1, CEBPA) (Supplementary Fig. S5E).  294 
To investigate the association between transcriptional changes and chromatin remodeling, we 295 
mapped open chromatin regions by ATAC-seq in FL progenitors 24 hours after EG induction. 296 
Most open chromatin regions were common between CTRL and iEG (33,429 peaks), while 297 
some were lost/decreased (12,412 Down peaks) or acquired/increased (5,975 Up peaks) in 298 
iEG cells (Fig. 5F, G, I). Notably, 29% of the genes deregulated in scRNAseq analyses showed 299 
differential ATAC-seq peaks around the genes' loci, suggesting that the transcriptional 300 
modifications induced by EG are partly due to chromatin remodeling (Fig. 5H). ATAC-seq also 301 
revealed differences between the CD41+ and Gr1+ iEG cell lines with Gr1+ cells showing mostly 302 
chromatin closing as compared to wild-type FL (1,899 Up and 16,383 Down peaks), while 303 
CD41+ cells showing more chromatin opening (34,167 Up and 19,971 Down peaks) (Fig. 5I). 304 
Notably, the regions opened by iEG in FL progenitors (5,975 Up peaks) at 24h were also 305 
enriched in CD41+ but not in Gr1+ cells, suggesting a closer proximity between iEG FL and 306 
CD41+ than with myeloid transformed cells (Fig. 5J).   307 
Motif analysis within the ETO2-GLIS2-specific gained open regions (Up peaks) showed a lower 308 
representation of GATA motifs and an increased representation of ETS/ERG motifs (Fig. 5K) 309 
in FL progenitors, in CD41+ and in Gr1+ cell lines compared to their representation within 310 
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regions specific for the control cells (Down peaks). Interestingly, motifs of some key myeloid 311 
transcription factors, including SPI and CEBP, were significantly enriched only in Gr1+ 312 
transformed cell, supporting a role for these factors in the transcriptional regulation in myeloid 313 
ETO2-GLIS2+ cells.  314 
Together, these data show that EG imposes more prominent transcriptional changes in fetal 315 
liver-derived than in adult HSC, in part, through rapid changes in chromatin accessibility to 316 
regions presenting binding sites for major hematopoietic transcription factors including GATA, 317 
ETS and CEBPA. 318 
 319 
GATA1 and CEBPA activities correlate with pediatric AML phenotypes  320 
HSC lineage specification involves TF expression or activity switches, including a SPI1/CEBPA 321 
module directing myeloid development (42,43) and an ERG/GATA1 balance (44) regulating 322 
the megakaryocytic fate and altered in human AMKL (10). As these TF are also involved in 323 
hematopoietic ontogeny (34,35), we investigated TF expression and functional contribution to 324 
EG-induced megakaryoblastic and myeloid phenotypes. Wild-type (CTRL) FL HSPC 325 
expressed more Gata1, Erg and Spi1 and less Cebpa than their ABM counterparts. Twenty-326 
four hours after iEG induction, all genes were downregulated excepted Erg in FL HSPC. 327 
However, iEG FL HSPC expressed significantly higher levels of Gata1 and Erg and lower 328 
levels of Cebpa and Spi1 than iEG ABM HSPC (Fig. 6A). Notably, Spi1 was more strongly 329 
downregulated by iEG in FL (4.9-fold) than in adult (2.2-fold) progenitors, consistently with 330 
scRNAseq data performed in purified LT-HSC (Fig. 5E). We then quantified expression of 331 
these TF in CTRL and iEG ABM LT-HSC- and MPP4-cells. Erg and Gata1 were more 332 
expressed in iEG LT-HSC-derived cells than in iEG MPP4-derived cells, while Cebpa and Spi1 333 
were highly expressed in MPP4 cultures (Fig. 6B). We then functionally assessed whether 334 
increasing ERG or GATA1 activity may impose a megakaryoblastic phenotype in iEG MPP4 335 
cells and whether increasing SPI1 or CEBPA activity biased iEG LT-HSC toward a myeloid 336 
phenotype (Fig. 6C-E). Retroviral GATA1, and to a lesser extent ERG, expression enhanced 337 
the megakaryocyte phenotype in iEG MPP4 cells. In iEG LT-HSC, expression of CEBPA, but 338 
not SPI1, enhanced the myeloid phenotype.  339 
We then compared ERG, GATA1, SPI1 and CEBPA expression levels in leukemic blasts from 340 
AMKL and AML patients and in different populations from the dual AML/AMKL phenotype 341 
patient (#5) (Fig. 6F and Supplementary Fig. S6A). AMKL cases showed high ERG and 342 
GATA1 and low SPI1 and CEBPA expression, while AML cases presented an opposite 343 
expression pattern. Similar profiles were observed in the human EG+ cell lines MO7e (AMKL) 344 
and CMS (AML) (Supplementary Fig. S1E). The EG+ case with a dual phenotype (#5) showed 345 
an intermediate expression of CEBPA, GATA1 and ERG compared to AMKL and AML patients 346 
(Fig. 6F). In this patient, the most immature CD34+CD41-CD15- blasts showed the highest 347 
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ERG expression compared to CD41+ and CD15+ blasts, while the CD41+ blasts showed the 348 
highest GATA1 expression and the CD15+ blasts showed the highest SPI1 expression levels. 349 
Notably, CD41+ blasts showed an unexpected combination of GATA1high and CEBPAhigh 350 
expression (Supplementary Fig. S6A), which significance for this peculiar case of dual 351 
megakaryoblastic/myeloid phenotype remains to be understood. 352 
Collectively, these data support the idea that the specific association between EG+ AMKL and 353 
young children results from a combination of at least two parameters (Fig. 6G). First, intrinsic 354 
differences in the GATA1 and CEBPA activities observed during the normal ontogeny (FL HSC 355 
vs. ABM HSC) and in the normal HSPC hierarchy (HSC vs. MPP) are conserved upon EG 356 
expression and correlate with the megakaryoblastic/myeloid phenotypic output, respectively. 357 
Second, EG induces a stronger deregulation of self-renewal-associated genes (e.g. ERG and 358 
SPI1) in the fetal vs. adult HSC. 359 
 360 
ETO2-GLIS2 reversibly transforms LT-HSC 361 
As our cellular and molecular observations indicate that EG hijacks of HSC properties, we 362 
compared the in vivo leukemogenic potential of purified cell populations and assessed its 363 
potential reversibility by tracking the differentiation potential of iEG-transformed cells (carrying 364 
the GFP reporter gene) after Dox removal.  365 
GFP+ FL LT-HSC and MPP3 from E14.5 iEG embryos, or LT-HSC and MPP cells from iEG 366 
ABM were transplanted into Dox-treated WT recipients (Fig. 7A). The iEG FL LT-HSC and 367 
MPP3 recipients developed fully penetrant and rapid (median: 27 days and 33 days) lethal 368 
leukemia (Fig. 7B). The iEG ABM LT-HSC recipients developed disease after a strikingly 369 
longer latency (median: 312 days, p=0.017) (Fig. 7B, C, Supplementary Fig. S6B). Only 1 out 370 
of 9 iEG ABM MPP3 recipients developed disease with a long latency and none of the iEG 371 
ABM MPP4 developed any disease (Fig. 7C, Supplementary Fig. S6B). The FL iEG LT-HSC 372 
and MPP3 recipients presented with a more severe disease than the ABM iEG LT-HSC mice 373 
as assessed by greater degree of splenomegaly, higher white blood counts, higher percentage 374 
of CD41+ cells and lower platelet counts, maturing myeloid populations and lymphoid cells in 375 
BM and spleen (Fig. 7D-G). Histological analyses showed that the BM, spleen and liver were 376 
infiltrated with GFP+ cells that were weakly VWF+. The iEG ABM LT-HSC recipients displayed 377 
rare maturing VWF+ megakaryocytes that were all GFP-, which was not observed in the iEG 378 
FL LT-HSC counterparts (Supplementary Fig. S6C, data not shown).  379 
To investigate the differentiation potential of LT-HSC-derived iEG leukemic cells, we purified 380 
the immature CD41+CD11b-Gr1- blasts from iEG FL LT-HSC diseased recipients and grew 381 
them in cultures in absence of Dox. As compared with the immature blasts maintained with 382 
Dox, they generated both maturing CD41+CD42+ megakaryocytes and CD11b+Gr1+ myeloid 383 
cells (Supplementary Fig. S6D). This was associated with reduced expression of iEG and its 384 
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known target Erg, while Gata1 expression increased, consistent with broad differentiation 385 
capacities (Supplementary Fig. S6E). To assess long-term hematopoietic potential, BM cells 386 
from the ABM LT-HSC-engrafted diseased recipients were transferred into secondary Dox-387 
treated recipients (Fig. 7H). Two weeks post-transplant (=D0 time point), when recipients 388 
showed the first signs of disease (Supplementary Fig. S6F, G), some recipients were 389 
maintained on Dox (Group A) while Dox-treatment was ceased in group B. At three days after 390 
Dox-removal, the platelets counts were back to normal in group B; 80% of platelets originated 391 
from iEG-transformed cells as shown by GFP expression (Fig. 7I). GFP+ cells were also 392 
detected later in RBC and WBC (Fig. 7I, Supplementary Fig. S6H). Notably, Dox-treated mice 393 
(group A) develop lethal leukemia similar to primary mice while group B off Dox did not (Dox+, 394 
Fig. 7J). Analysis of group B at six-months post Dox removal demonstrated that GFP+ cells 395 
where still present in all analyzed hematopoietic compartments, including mature B and T cells 396 
(Fig. 7K, Supplementary Fig. S6I). Together, these data show that iEG expression in FL LT-397 
HSC results in a rapid and aggressive AMKL in vivo associated with maintenance of long-term 398 
HSC-like differentiation potential once the driver oncogene is switched off. 399 
 400 
MLL-AF9 expression in fetal liver LT-HSC induces megakaryoblastic features 401 
In addition to ETO2-GLIS2, other fusion oncogenes, including MLL-AF9, are found in both 402 
pediatric AML and AMKL. However, published murine models only displayed MLL-AF9-driven 403 
myeloid, but not megakaryoblastic leukemic phenotypes. To assess whether the ontogenic 404 
stage and cell hierarchy also affects the phenotype induced by MLL-AF9, we retrovirally 405 
expressed MLL-AF9 (rMLL-AF9) in FL- and ABM-derived HSPC from WT mice. Notably, rMLL-406 
AF9 resulted in an increased CD41+ megakaryoblastic phenotype in FL compared to ABM 407 
cells (Supplementary Fig. S7A). Next, we transduced purified FL LT-HSC and MPP 408 
populations and observed an increased the CD41+ output only with LT-HSC (Supplementary 409 
Fig. S7B). Transplantation of rMLL-AF9-transduced cells revealed disease development in 410 
both cases presenting with clear CD41+ and VWF+ megakaryoblastic features only in recipients 411 
of FL LT-HSC, but not MPP4 cells (Supplementary Fig. S7C, D). rMLL-AF9-expressing CD41+ 412 
blasts also expressed high Gata1 and low Spi1 and Cebpa expression, while MPP4-derived 413 
myeloid blasts showed a mirrored expression pattern (Supplementary Fig. S7E). Collectively, 414 
these observations indicate that ontogenic changes in the cellular hierarchy impact disease 415 
phenotypes not only for ETO2-GLIS2 but also for other AMKL-associated fusion oncogenes 416 
like MLL-AF9.  417 
 418 





In toto, our observations in patient samples and in inducible transgenic mouse models for 422 
pediatric leukemia-associated fusion oncogenes, including ETO2-GLIS2 and MLL-AF9, 423 
provide experimental evidence that aggressive pediatric AMKL originates in fetal HSPC and, 424 
more globally, that age and phenotype-specific associations observed in human patients rely 425 
on changes in the cellular architecture during hematopoietic ontogeny.    426 
A novel inducible transgenic mouse model allowed us to demonstrated that expression of EG 427 
in fetal progenitors and adult LT-HSC, but not in further committed adult progenitors, resulted 428 
in leukemogenesis in vivo. The previous lack of in vivo transformation (Dang et al., 2017; 429 
Gruber et al., 2012, and our unpublished data) could therefore be due to a poor targeting of 430 
LT-HSC by retroviral transduction. The inducible model was also instrumental in demonstrating 431 
that HSC-derived EG+ leukemic cells can maintain long-term reconstitution and differentiation 432 
properties upon withdrawal of the driver oncogene. In adult hematopoiesis, several cellular 433 
and gene expression studies have indicated the close proximity between LT-HSC and 434 
megakaryocytic states in normal and stress conditions (22–24,29,46,47), thus prompting the 435 
hypothesis that megakaryopoiesis may represent the native differentiation pathway for LT-436 
HSC (24). Our data indicate that EG alters master hematopoietic TF activities in LT-HSC (e.g. 437 
ERG, HLF, MECOM and HOX-related factors) toward a megakaryoblastic state and therefore 438 
strongly suggest that EG+ AMKL is mostly a LT-HSC disease. In addition, expression of MLL-439 
AF9 in fetal LT-HSC led to clear megakaryoblastic features as opposed to fetal MPP or adult 440 
progenitors that generated the typical MLL-AF9 myeloid leukemia. Also, other AMKL fusion 441 
involves transcription regulators important for both normal HSC and megakaryocyte biology 442 
(e.g. OTT1/RBM15)(48). Therefore, we propose a conceptual framework for pediatric AMKL 443 
in general in which transcriptional constraints, imposed by distinct oncogenes, represent 444 
molecular switches that functionally converge on an early alteration of fetal LT-HSC as they 445 
engage the native megakaryocytic differentiation pathway.  446 
This study also demonstrates that the transforming potential of pediatric oncogenes is 447 
dependent on the ontogeny-related dynamics of the hematopoietic tissue architecture. Indeed, 448 
in our model, iEG expression in fetal LT-HSC generated an aggressive and phenotypically 449 
homogeneous megakaryoblastic phenotype, while expression in adult LT-HSC resulted in the 450 
development of more heterogeneous phenotypes with delayed latencies. This is consistent 451 
with recent findings that normal fetal hematopoiesis is primarily controlled by multipotent HSPC 452 
(endowed with megakaryocytic potential), while adult hematopoiesis presents with a higher 453 
ratio of committed progenitors (lacking megakaryocytic potential)(26). Molecularly, our data 454 
indicate that, while GATA1 and CEBPA expression are both low in EG+ leukemia, their relative 455 
activities may contribute to the megakaryoblastic vs. myeloid phenotype of EG+ leukemia, 456 
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respectively. EG imposed higher Erg and lower Spi1 levels in fetal than in adult LT-HSC, but 457 
engineered expression of these factors did not drastically impact the EG-induced phenotype 458 
in vitro. Notably, the precise expression level of Erg and Spi1 controlled self-renewal and 459 
transformation in other models (49–51). Together, we propose that the association between 460 
EG+ AMKL and the young age of the patients results from the combination of 1-intrinsic 461 
differences between normal fetal and adult hematopoiesis together with 2-a stronger alteration 462 
of fetal HSC transcriptional regulation by EG, leading to a higher susceptibility of fetal HSC to 463 
transformation by EG (Fig. 6G). The former includes a higher proportion of multipotent vs. 464 
myeloid-committed progenitors and a higher GATA1 vs. CEBPA activity in fetal as compared 465 
to adult stages. The latter includes more a prominent deregulation by EG of a self-renewal 466 
module (e.g. ERG and SPI1). As low CEBPA activity was also associated with increased 467 
competitive advantage and proliferation (35,52), the lower CEBPA expression in the EG+ fetal 468 
context may also contribute to the more aggressive leukemia obtained upon EG expression in 469 
fetal HSC.       470 
It is likely that the importance of this higher ontogeny-related susceptibility extend to the other 471 
human megakaryocyte/platelet-related diseases (e.g., Trisomy 21 AMKL and 472 
thrombocytopenia absent radii syndrome)(53–55) but also to other pediatric leukemia, 473 
including lymphoid leukemia with MLL-AF4 (56), which prevalence peaks during childhood. 474 
Furthermore, multiple pediatric cancers are driven by strong epigenetic fusion oncogenes in 475 
the context of a low mutational burden, including Ewing's sarcoma and rhabdomyosarcoma, 476 
for which the cellular origin is poorly defined (13), and glioblastoma, for which oncogenic 477 
drivers have been recently shown to arise in stem cells (57). Therefore, a precise 478 
characterization of the changes in the cellular architecture of the relevant tissues of origin 479 
should improve our understanding of the heterogeneous clinical presentations in other 480 
pediatric cancers and facilitate the establishment of other disease models that may serve as 481 
experimental platforms to develop more selective therapeutic strategies.   482 
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Reagents and resources  532 
Table S10 contains an extensive list of the relevant reagents. 533 
 534 
Patient-derived data and material 535 
Patient blood and BM samples were obtained with the informed consent of the patient or their 536 
family in accordance with national ethics law. Samples were subjected to Ficoll gradient, 537 
immunophenotyped, and used fresh or frozen in fetal bovine serum (FBS) supplemented with 538 
10% DMSO for subsequent use. DNA and RNA were obtained from the mononuclear cell 539 
fractions using the manufacturer's recommendations (Qiagen). cDNA from 284 patients were 540 
available to detect the EG fusion via RT-PCR. The primer sequences are provided in Table 541 
S11. 542 
Clinical data were obtained from the ELAM02 protocol. The present study focused on 385 of 543 
438 children treated in the ELAM02 trial (Treating Patients with Childhood Acute Myeloid 544 
Leukemia with Interleukin-2; ClinicalTrials.gov NCT00149162)(37). Patient selection was 545 
based on the availability of genomic DNA and RNA upon AML diagnosis. Children aged 0 to 546 
18 years newly diagnosed with AML were enrolled between March 2005 and December 2011. 547 
Patients diagnosed with acute promyelocytic leukemia, therapy-related AML or Down 548 
syndromes were excluded from the ELAM02 trial. The study was approved by the Ethics 549 
Committee of Saint-Antoine Paris University Hospital (Assistance Publique-Hôpitaux de Paris) 550 
and by the Institutional Review Board of the French Regulatory Agency. The study was 551 
conducted in accordance with the declaration of Helsinki. Data concerning age at diagnosis 552 
was also collected from the ELAM02 protocol and (9) including 87 AMKL patients. 553 
 554 
Patient-Derived Xenotransplantation (PDX) 555 
Patient-derived xenograft protocols have been described previously (8).  556 
 557 
FISH 558 
The DNA probe set obtained from Empire genomics (CBFA2T3 and GLIS2 FISH probes, 559 
AmpliTech, Compiègne, France) hybridizes to chromosome 16p13.3 at CBFA2T3 locus (Red) 560 
and 16q24.3 at GLIS2 (green) in normal metaphase spreads or interphase nuclei. FISH 561 
analysis was performed following the manufacturer's protocol. Interphase nuclei and 562 
metaphases were scored on Imager Z2 fluorescence microscope (Zeiss, France) using 563 
Isis/Metafer/Relosys MetaSystems Software (MetaSystems, Altlussheim GmbH, Germany). In 564 
cells with the EG fusion, the overlap between the two probes generates a yellow signal 565 
indicative of the fusion oncogene.  566 
 567 
Cell lines 568 
The human AMKL MO7e cells (58) (derived from a 6-month-old girl) were cultured in MEM-α 569 
supplemented with 20% FBS, Penicillin (100U/mL)-Streptomycin (100μg/mL), 2mM L-570 
Glutamine (Gibco) and 5 ng/ml of human GM-CSF (PeproTech).  571 
The human CMS cells (59) (derived from a 2-years-old girl) were cultured in RPMI1640 572 
supplemented with 10% FBS, Penicillin (100U/mL)-Streptomycin (100μg/mL), and 2mM L-573 
Glutamine (Gibco). 574 
The human AML-M6 HEL 92.1.7 (HEL) cells (60) (derived from a 30-years-old patient) were 575 
cultured in RPMI1640 supplemented with 10% FBS, Penicillin (100U/mL)-Streptomycin 576 
(100μg/mL), and 2mM L-Glutamine (Gibco).  577 
All cell lines were obtained from the laboratory of O. Bernard in 2009, were karyotyped for 578 
authentication in 2018, were tested for mycoplasma in 2017 and the described experiments 579 
were performed within 3 months after thawing. 580 
 581 
Mice 582 
To generate the iETO2-GLIS2:rtTA (iEG) model, the human EG cDNA was cloned into the 583 
p2Lox vector and electroporated into A2Lox-Cre embryonic stem (ES) cells, a generous gift 584 
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from Michael Kyba (61). ES cell clones were selected for the correct integration of EG at the 585 
Hprt locus on chromosome X and used to obtain germline-transmitting chimeras that were 586 
subsequently backcrossed into the C57BL/6 background. Genotyping of the reverse 587 
tetracycline-controlled transactivator (rtTA) and the EG transgene were genotyped using the 588 
primers indicated in Table S11. 589 
To obtain GFP+-expressing iEG mice and track the iEG cells upon in vivo transplantations, we 590 
crossed iETO2-GLIS2:rtTA with the Ubiquitin-GFP reporter line (UBI-GFP) mice (62). In these 591 
mice, GFP expression is controlled by an ubiquitous promoter and not controlled by Dox. 592 
Therefore, engraftment of all CTRL and iEG donor cells can be tracked using GFP regardless 593 
of the Dox treatment status or iEG expression. 594 
The transgenic mouse line for inducible expression of MLL-AF9 has been described previously 595 
(25). 596 
The iETO2-GLIS2 and iMLL-AF9 transgenes were induced with doxycycline provided in 597 
impregnated food pellets (Dox food pellets, 545 mg/kg, Provider: SSNIF), which is predicted 598 
to correspond to an approximate dose of 2.2 mg/day. 599 
Mice were maintained at the Gustave Roussy preclinical facility and all experiments were 600 
approved by the French National Animal Care and Use Committee (CEEA 26: #2012-017, 601 
#201712180922196_v2 and #2017122111548235_v2). 602 
 603 
Bone Marrow Transplantation 604 
Transplantation of bone marrow (BM, 106) or sorted progenitor cells were performed through 605 
intravenous injection in lethally (9.5 Gy) or sub-lethally (5Gy) irradiated 8-week-old C57BL/6 606 
recipient mice.  607 
Morphologic analysis of peripheral blood, BM, and spleen cells as well as histological analyses 608 
were performed according to standard procedures. 609 
 610 
Flow Cytometry 611 
Cells analyzed by flow cytometry were antibody stained in PBS 1X supplemented with 2% FBS 612 
for 30 minutes at 4°C with washing prior to FACS analysis. Whole BM and spleen cells from 613 
mice were collected, subjected to RBC lysis and stained for FACS analysis. 614 
To obtain hematopoietic stem and progenitor cells (HSPC), BM cells were depleted from the 615 
mature hematopoietic cells (Lin-) with the Becton Dickinson (BD) Mouse Hematopoietic 616 
Progenitor (stem) Cell enrichment Set (558451).  617 
To obtain adult BM (ABM) precise progenitors populations were further purified by FACS 618 
according to the following phenotypes: LT-HSC (HSC) were defined as LIN-Kit+Sca1+CD135-619 
CD34-CD48-CD150+, MPP2 cells were defined as LIN-Kit+Sca1+CD135-CD34+CD48+CD150+, 620 
MPP3 cells were defined as LIN-Kit+Sca1+CD135-CD34+CD48+CD150-, and MPP4 cells were 621 
defined as LIN-Kit+Sca1+CD135+CD34+CD48+CD150-.  622 
To obtain fetal liver HSPC, cells were depleted with Biotin-conjugated antibodies against CD3, 623 
Ter119, B220, Gr1, NK1.1, F4/80, CD19. 624 
To obtain FL HSC and progenitor populations, cells were purified by FACS according to the 625 
following phenotypes:  LT-HSC were defined as LIN-Kit+Sca1+CD135-CD48-CD150+, while 626 
MPP2, MPP3 and MPP4 cells were defined with the same markers as ABM cells. 627 
Flow cytometry analyses were performed with an ARIAII, ARIAIII, CANTO-II or CANTO-X 628 
instruments (BD), and data were analyzed using FlowJo software (version Flowjo 9.3.2). 629 
 630 
Serial replating assays 631 
Total cells and/or progenitors from ABM or FL at E12.5 or E14.5 were isolated from iEG mice 632 
and plated in 3mL methylcellulose (Methocult M3434; StemCell Technologies, Canada), 633 
supplemented with IL3, IL6, SCF, EPO and 300ng/ml DOX. Colonies were scored under the 634 
microscope after five to seven days, harvested and replated (104 cells) for four rounds. 635 
 636 
Single cell cultures 637 
Single cells were seeded in 96-well plates in 100ul RPMI supplemented with 10% FBS, 638 
cytokines (mIL3, mIL6, mIL11, mSCF, mTPO, mEPO, mGM-CSF, mFLT3l) and 100ng/ml Dox. 639 
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Wells were scored for clonal growth after four days of culture and frequency of 640 
megakaryoblastic and myeloid cells was assessed by surface marker analysis using a 641 
previously described method (63) after five to ten days. 642 
 643 
RNA extraction & quantitative RT-PCR analysis 644 
mRNA was isolated using an RNeasy Mini/Micro kit (Qiagen) and quantified using a NanoDrop 645 
(ThermoScientific). Reverse transcription was carried out with SuperScript II (Invitrogen). Q-646 
PCR was performed with SYBR Select Master Mix or Taqman Gene Expression Master Mix 647 
(Applied Biosystems) using a 7500HT Fast Real-Time PCR System (Applied Biosystems) 648 
according to the manufacturer's recommendations. The primer sequences are provided in 649 
Table S11. 650 
 651 
ETO2-GLIS2 genomic DNA fusion point 652 
DNA were isolated using an All Prep DNA/RNA Mini/Micro kit (Qiagen) and quantified using a 653 
NanoDrop (ThermoScientific). PCR was performed using a GeneAmp PCR System 9700. The 654 
primer sequences are provided in Table S11. 655 
 656 
Immunoblotting 657 
Total cell lysates were prepared in lysate buffer containing 50 mM Tris-HCl (pH 8), 150 mM 658 
NaCl, 1% NP40, 1 mM EDTA, 0.1% SDS, 0.5% DOC, and protease inhibitors (PMSF 1X, NAF 659 
1X, Sodium orthovanadate 1X, complete 1X). Western blotting was then performed using 660 
standard procedures using anti-ETO2 (ab33072, Abcam), anti-HSC70 (sc7298, Santa Cruz 661 
Biotechnology) and anti-RPLP0 (ab192866, Abcam) antibodies. 662 
 663 
Production of retroviral particles and transduction 664 
For retroviral transduction experiments, we constructed murine stem cell virus (MSCV) 665 
backbone constructs expressing GFP and encoding human ETO2-GLIS2, ERG, CEBPA, 666 
SPI1, GATA1 ORF. Briefly, 293T cells were transfected using Xtreme GENE transfection 667 
reagent according to the manufacturer’s instructions (Roche). Retroviral particles were 668 
harvested 24 and 48 hours after transfection. For retroviral transduction, murine progenitor 669 
cells were spinoculated twice with retroviral particles in culture media containing 5 μg/mL 670 
polybrene and 7.5 mM HEPES buffer for 90 minutes at 2500 rpm and 33°C. 671 
 672 
Single cell RNAseq (scRNAseq) 673 
Progenitor cells were isolated from iEG mice and cultured for 24 hours in RPMI supplemented 674 
with 10% FBS, cytokines (mIL3, mIL6, mSCF, mTPO, mFLT3l) and 100 ng/ml Dox. ScRNAseq 675 
analysis was performed as described previously (28,64). Single cells were individually sorted 676 
in 96-well plates containing lysis buffer (0.2% Triton X-100 and 500U/ml Superase-In RNase 677 
Inhibitor). The Illumina Nextera XT DNA preparation kit was used to prepare libraries. Pooled 678 
libraries were sequenced using the Illumina Hisequation 4000 system (single-end 125 base 679 
pair reads).  680 
 681 
Statistical analyses 682 
Statistical analyses were performed using the GraphPad Prism software (version Prism 6-2) 683 
except otherwise mentioned. 684 
 685 
Bioinformatics analyses 686 
Reads quality control and alignment: Quality control of reads was performed using FastQC 687 
0.11.7 and multiQC 1.5.dev0. The reads were aligned to the reference genome mm10 688 
GRCm38.p4 81 with GSNAP (v 2015-09-29) with the following parameters: -A sam -B 5 -t 23 689 
-n 1 -Q -N 1. Finally, gene expression was quantified using HTSeq 0.6.0 690 
Counts pre-processing, quality controls and normalization: prior to data normalization, cells 691 
were filtered to remove low quality samples and to fulfil the following conditions: have at least 692 
4000 detectable genes, have less than 20% of counts mapping to mitochondrial genes, have 693 
less than 50% of reads mapping to spike in controls and at least 25 counts that map to nuclear 694 
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genes. Normalization was next performed by library size with the deconvolution of size factors 695 
method described by Lun et al. using scran and scater R libraries (65,66)⁠. Pre-clustering of 696 
cells and five pool sizes from 20 to 100 (by an increment of 20) were used as normalization 697 
parameters.  High variable genes (HVG) selection was performed as previously described (67) 698 
for feature selection. Those HVG were used for t-SNE to explore possible underlying 699 
substructures in the data.  700 
Differential expression analysis and gene set enrichment analysis (GSEA): for detection of 701 
differences at the transcriptomic level between groups, differential expression analysis was 702 
performed with Wilcoxon test over the log2 counts values and p-value correction by Benjamini-703 
Hochenberg (FDR cut-off at 0.05). GSEA was also performed to detect potential 704 
overexpressed signatures in patients with default parameters except for –collapse false –705 
permute phenotype (68).⁠  706 
Gene Regulatory Network inference: ARACNe-AP software was used to infer a Gene 707 
Regulatory Network (69) using iEG scRNAseq data to predicted a list of target genes of each 708 
TF in the context of cells expressing ETO2-GLIS2 (called "EG network", Table S6). For that 709 
purpose, iEG cells with log2 counts < 1 for ETO2-GLIS2 were not considered. ARACNe was 710 
ran over the log2 normalized counts in bootstrap mode (100 iterations), with a p-value 711 
threshold of 1e-8 and a custom curated list of 2171 TFs. Similarly, we predicted the target 712 
genes of each TF in a normal hematopoietic context from published scRNAseq data (70) 713 
obtained with the same protocol (called "normal network", Table S7). Therefore, the activity of 714 
each TF was computed using two independent lists of target genes and consistent prediction 715 
of TF activity levels were obtained for key factors (Figure 5E).  716 
Transcription regulator activity prediction and Master Regulator Analysis: networks were used 717 
to infer activity (Normalized Enrichment Score, NES) of the transcriptomic regulator with R 718 
library viper (71), as described in the package manual. NES were used to test differential 719 
activity by t-test and p-value correction by Benjamini-Hochenberg (FDR cut-off at 0.05). Master 720 
Regulator Analysis was also carried out as described in the manual, with calculation of 721 
bootstrapped null model and shadow correction (enrichment of a regulator driven by similar 722 
targets of another regulator) of top 25 regulators.  723 
 724 
ATACseq 725 
ATACseq analysis has been adapted from (Buenrostro JD, 2015). Briefly, cells were isolated 726 
from iEG mice and cultured for 24 hours in RPMI supplemented with 10% FBS, cytokines 727 
(mIL3, mIL6, mSCF, mTPO, mFLT3l) and 100 ng/ml Dox. After cell lysis, transposition and 728 
purification step, the transposed DNA fragments were amplified by polymerase chain reaction 729 
(PCR) between 12 and 18 depending on the number of cells at the beginning (50,000 to 6,000) 730 
using adapters from the Nextera index kit (illumina). PCR purification was performed using 731 
Agencourt AMPure XP magnetic beads (Beckman Coulter A63880) in order to remove large 732 
fragments and remaining primers. Library quality was assessed using an Agilent 2100 733 
Bioanalyzer using a High Sensitivity DNA chip (Agilent Technologies 5067-4626). Libraries 734 
were sequenced using Novaseq-6000 sequencer (Illumina) (50bp paired-end reads).  735 
Quality control of reads was performed using FastQC 0.11.7 and multiQC 1.5. The reads were 736 
aligned to the reference genome mm10 with bwa (aln 0.7.17). After alignment, we removed 737 
reads mapping to the mitochondrial genome, PCR duplicate reads and reads with a mapping 738 
quality lower than 20 using samtools (v 1.9). Final read counts for all mouse datasets ranged 739 
from 37 to 128 million reads. Mapped reads were normalized to bins per million (BPM) and 740 
were converted to bigwig format using deeptools (v3.2.0). Peak calling, differential analysis, 741 
annotation and motif analysis was performed using macs2 (V 2.1.2), Diffbind R package (v 742 
2.8.0 in R-3.5.1 with threshold log2(1.5)), and homer (v4.10.4, annotatePeak.pl and 743 
findMotifsGenome.pl) respectively. 744 
 745 
Data availability 746 
Single cell RNAseq data were deposited into EBI - Array-Express under the accession number 747 
E-MTAB-7213.  748 
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FIGURE LEGENDS 964 
 965 
Figure 1.  966 
AMKL is diagnosed at a younger age than AML in pediatric patients.  967 
A, Representative fluorescent in situ hybridization with probes detecting ETO2 (Green) and 968 
GLIS2 (Red) in leukemic cells from an EG+ AML patient. The yellow signal results from the 969 
red-green overlap, thus indicating the derivative chromosome carrying the EG fusion.  970 
B, Frequencies of EG+ patients with AMKL (n=34), other AML subtypes ("AML M0-5", n=242) 971 
and in the entire ELAM02 cohort ("All AML", n= 276).  972 
C, Age at diagnosis of EG+ patients obtained from pooling data from the ELAM02 cohort and 973 
published reports (9,12,72–75). AMKL (n=33) vs AML (n=15), p<0.0001.  974 
D, Age at diagnosis of NUP98-KDM5A+ patients, AMKL (n=27) vs AML (n=4), p=0.0017.  975 
E, Age at diagnosis of patients with MLL fusions, AMKL (n=18) vs AML (n=88), p=0.095.  976 
F, Age at diagnosis of patients with AMKL (n=132) vs. other AML (n=500) subtypes, p<0.0001.  977 
G, Flow cytometry analyses of primary patient-derived xenografts (PDX) obtained from AMKL 978 
and AML patients. Analyses are gated on CD34+ human blasts.  979 
H, Experimental design of flow cytometric sorting of the three blast populations analyzed in (I-980 
K).  981 
I, Representative cell morphology of the three leukemic cell populations on cytospots. Wright-982 
Giemsa staining. Magnification: x100.  983 
J, Secondary xenotransplantation of various cell populations from patient #5 indicates that only 984 
CD41-CD15- cells propagated the disease.  985 
K, CD15 and CD41 expression on CD34+ cells obtained from recipients of 3x105 CD15-CD41- 986 
cells one-year post-transplant. 987 




Figure 2.  992 
ETO2-GLIS2 efficiently induces leukemia in mice.  993 
A, Experimental design: disease-inducing potential was assessed by providing doxycycline 994 
(Dox) to naive iEG female mice (primary). Cell autonomous leukemogenesis was ascertained 995 
by transplanting 106 BM cells from iEG mice induced at eight weeks of age and for 45 days 996 
into wild-type C57BL/6 recipients with or without exposure to Dox (secondary).  997 
B, Representative flow cytometry analysis of Kit+ and CD41+ expression (upper panels) or 998 
CD11b+ and Gr1+ expression (lower panels) in Bone Marrow of primary diseased iEG mice 999 
defining 2 phenotypes: Group1=megakaryoblastic (primarily CD41+) and 1000 
Group2=immature/myeloid (heterogeneous expression of Kit+ and CD11b+Gr1+ markers) 1001 
(CTRL n=5, iEG n=19 in total).  1002 
C, Spleen histology of primary mice (CTRL, Group 1 and Group 2). Upper panels: 1003 
Hematoxylin-Eosin-Safran staining, lower panels: VWF staining (brown coloration). 1004 
D, Kaplan-Meier survival plot of Dox-exposed iEG mice according to the two phenotypes 1005 
described in (B) (CTRL n=11, iEG n=19 in total, CTRL vs. Group1: p=0.0001, CTRL vs. 1006 
Group2: p<0.0001). Median survival: Group 1=164 days, Group2 = 251 days. 1007 
E, Spleen and liver weights in primary iEG mice according to the two phenotypes described in 1008 
(B) (1 = CD41+ and 2 = immature/CD11b+Gr1+). Spleen (CTRL vs. Group1: p=0.0002, CTRL 1009 
vs. Group2: p=0.0023), liver (CTRL vs. Group1: p=0.0060, CTRL vs. Group2: p=0.0016).  1010 
F, Peripheral blood counts of diseased iEG mice with the different phenotypes. RBC (CTRL 1011 
vs. Group1: p<0.0001, CTRL vs. Group2: p<0.0001), WBC (CTRL vs. Group1: p=0.0068, 1012 
CTRL vs. Group2: p=0.7624), Platelet (Plt: CTRL vs. Group1: p=0.3902, CTRL vs. Group2: 1013 
p=0.6533).  1014 
G, Kaplan-Meier survival plot of secondary recipients with or without Dox-exposure (Dox -: 1015 
n=4, Dox +: n=6). p=0.0110 (Log rank Mantel-Cox test).  1016 
H, Representative spleen section of a secondary recipient stained with VWF (brown coloration) 1017 
shows significant organ infiltration.  1018 
 
 25 
I, Spleen and liver weights in secondary recipients with or without Dox-exposure. Spleen: 1019 
p=0.0025, liver: p=0.0220.  1020 
J, Quantification of flow cytometry analyses in the spleen of secondary recipients with or 1021 
without Dox-exposure. Kit+: p=0.0026, CD41+: p=0.0015, CD11b+Gr1+: p=0.1002. 1022 
Statistical significance is indicated as p values (Student’s t test except when otherwise 1023 
specified). *: p<0.05, **: p<0.01, ***: p<0.001. 1024 
 1025 
 1026 
Figure 3.  1027 
Developmental stage determines the phenotype of ETO2-GLIS2+ leukemia.  1028 
A, Experimental design to address the impact of EG on the clonogenic potential of fetal liver 1029 
(FL) or adult bone marrow (ABM) progenitors in methylcellulose shown in (B) and (C) or in vivo 1030 
shown in (D to H).  1031 
B, Number of colonies upon culture of 2,500 fetal liver (FL E12.5) or Lin- BM cells at two weeks 1032 
(newborn) or two months post-partum (ABM) in Dox-containing methylcellulose conditions. 1033 
Serial replating was performed every seven days. P1: first plate, P2: secondary plate, P3: 1034 
tertiary plate, P4: quaternary plate, P5: fifth plate. FL P5 p<0.0001, newborn P4 p=0.0034, 1035 
ABM P4 p=0.0246. 1036 
C, Representative flow cytometry analysis of CD41+ and Gr1+ expression at P3 (upper panels) 1037 
and percentages of CD41+ and Gr1+ cells at P1 to P3 (lower panels).  1038 
D, Kaplan-Meier survival plot of wild type Dox-treated recipients engrafted with 1x106 ABM or 1039 
FL cells from double transgenic iEG+Ubiquitin-GFP+ (GFP+). Log rank Mantel-Cox test: 1040 
p<0.0001. Median survival FL = 39 days, ABM = 397 days. 1041 
E, Spleen weights in CTRL and diseased mice at time of sacrifice (CTRL vs. FL: p=0.0005, 1042 
CTRL vs. ABM: p=0.1999, FL vs. ABM p<0.0001). 1043 
F, Peripheral blood counts of recipients of FL and ABM. WBC (CTRL vs. FL: p=0.0037, CTRL 1044 
vs. ABM: p=0.9125, FL vs. ABM p<0.0001), RBC (CTRL vs. FL: p=0.0004, CTRL vs. ABM: 1045 
p=0.0041, FL vs. ABM p=0.0133), Platelets (Plt: CTRL vs. FL: p=0.0003, CTRL vs. ABM: 1046 
p=0.0137, FL vs. ABM p=0.0181). 1047 
G, Representative flow cytometry analyses of BM cells from diseased recipients at time of 1048 
sacrifice. 1049 
H, Quantification of GFP+ (CTRL vs. FL: p=0.2644, CTRL vs. ABM: p<0.0001, FL vs. ABM 1050 
p<0.0001), CD41+ (CTRL vs. FL: p=0.0154, CTRL vs. ABM: p=0.1870, FL vs. ABM p<0.0001) 1051 
and CD11b+Gr1+ (CTRL vs. FL: p=0.0024, CTRL vs. ABM: p=0.6335, FL vs. ABM p=0.0167) 1052 
in GFP+ BM cells. 1053 
I, Images of E14.5 embryos (left and middle panels) and corresponding FL (right panels) 1054 
obtained from pregnant females on Dox for 36 hours. 1055 
J, Flow cytometry analyses of FL cells obtained in (I) (CTRL n=8, iEG n=10). CD71+Ter119+: 1056 
p<0.0001, CD11b+Gr1+: p=0.0380, CD41+: p<0.0001. 1057 
Statistical significance is indicated as p values (Student’s t test except when otherwise 1058 
specified). *: p<0.05, **: p<0.01, ***: p<0.001. 1059 
 1060 
 1061 
Figure 4.  1062 
ETO2-GLIS2-induced AMKL is an HSC-derived leukemia.  1063 
A, Experimental design to address the clonogenic potential of HSC and MPP from CTRL and 1064 
iEG E14.5 embryos. Serial replating was performed every seven days for four weeks (P1 to 1065 
P4).  1066 
B, Representative flow cytometry analyses of cells obtained from the first plate (P1).  1067 
C, Number of colonies upon serial replating. Mean+/-SEM is indicated.  1068 
D, Representative flow cytometry analyses of cells grown in methylcellulose cultures with and 1069 
without Dox.  1070 
E, Experimental design to address the clonogenic potential of adult (8-10 weeks-old) HSC and 1071 
MPP from iEG and CTRL mice.  1072 
F, Representative flow cytometry analyses of cells obtained at P1.  1073 
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G, Number of colonies upon serial replating. Mean+/-SEM is indicated.  1074 
H, Wright-Giemsa stained cytospots from iEG ABM HSC- and MPP4-derived methylcellulose 1075 
cultures at P3. Magnification: x100.  1076 
I, Single HSC and MPP3 ABM cells from CTRL or iEG mice were evaluated for their potential 1077 
to develop myeloid (Gr1+), megakaryoblastic (CD41+) or mixed cell populations (containing 1078 
both Gr1+CD41- and Gr1-CD41+ cells) in 96-wells liquid cultures with Dox treatment. A 1079 
representative flow cytometry analysis of the three types of colonies obtained after eight days 1080 
of culture is shown.  1081 
J, Histogram representing the percentages of CD41+, Gr1+ or mixed population colonies as 1082 
defined in (I), (HSC CTRL: n=50, HSC iEG: n=47, MPP3 CTRL: n=53 and MPP3 iEG: n=85). 1083 
 1084 
 1085 
Figure 5.  1086 
ETO2-GLIS2 alters the LT-HSC transcriptional network in an ontogeny-dependent 1087 
manner 1088 
A, Clustering of the different populations based on scRNAseq data using Zinbwave. The 1089 
number of genes significantly differentially expressed between CTRL vs. iEG in each 1090 
population is indicated. 1091 
B, Gene Set Enrichment Analysis on iEG FL LT-HSC (left panel) or ABM LT-HSC (right panel) 1092 
vs. CTRL scRNAseq data using published EG+ AMKL patients' specific gene expression 1093 
signatures from Bourquin et al. (40) or Gruber et al. (41). Enrichment score (NES) in iEG vs. 1094 
CTRL are represented (positive NES indicates higher activity in iEG vs CTRL cells, negative 1095 
NES indicates lower activity in iEG vs CTRL cells). Up: signature of genes upregulated in EG+ 1096 
AMKL patients, Down: signature of genes downregulated in EG+ AMKL patients. *: FDR<0.25, 1097 
**: FDR<0.05, ***: FDR<0.01. 1098 
C, GSEA using published signatures from normal progenitors and mature cells (38,76): HSC, 1099 
MPP2, MPP3, MPP4, Mono: Monocyte, Neutro: Neutrocyte and MK: Megakaryocyte. 1100 
D, Violin plots of Myct1, Esam and Vwf expression in FL and ABM LT-HSC. Log2 values of 1101 
the normalized read counts are represented.  1102 
E, Violin plots of Spi1, Nfe2 and Mpl expression in FL and ABM LT-HSC. Log2 values of the 1103 
normalized read counts are represented.  1104 
F, Heatmap hierarchical clustering centered on open chromatin peaks identified by ATACseq 1105 
analysis in CTRL and iEG FL progenitors (LT-HSC+MPP1+MPP2) after 24h of Dox induction. 1106 
Common: = peaks unchanged between CTRL and iEG; Down: = peaks lost or significantly 1107 
reduced in iEG; Up: = peaks gained or significantly enriched in iEG. Windows of 11kb are 1108 
shown. S: peak start, E: peak end.  1109 
G, Illustrations of ATAC-seq peaks in CTRL and iEG FL progenitors of representative common 1110 
(Rplp0), Down (Nfe2) and Up (Esam) peaks using IGV software.  1111 
H, Pie chart illustrating the fraction of significantly deregulated genes in scRNAseq iEG vs. 1112 
CTRL FL-HSC in which a modified EG peaks (either Up or Down) is present. The number of 1113 
genes with a deregulated peak is indicated.   1114 
I, Histogram representation of the number of Common, Up and Down peaks between iEG FL 1115 
progenitors, CD41+ cell line or Gr1+ cell line and CTRL FL progenitors.  1116 
J, Intensity profiles of Up peaks in FL progenitors described in (F) with CTRL and iEG FL 1117 
progenitors, CD41+ and Gr1+ ATACseq data.   1118 
K, Motifs analysis under the peaks enriched in CTRL vs. iEG (Down peaks) in FL progenitor 1119 
(peaks Down in iEG FL progenitors, dark grey), in iEG vs. CTRL (peaks Up in iEG FL 1120 
progenitors, green), in megakaryoblastic CD41+ (CD41, orange) and in myeloid Gr1+ (Gr1, 1121 
Blue) iEG cell lines. Chi2 analysis: GATA: FL vs. Down p=3.46e-143, CD41 vs. Down p=3.67e-1122 
316, Gr1 vs. Down p=6.77e-68 ; ERG: FL vs. Down p=1.19e-10, CD41 vs. Down p=6.5e-32, Gr1 1123 
vs. Down p=2.31e-15 ; PU.1: FL vs. Down p=0.21, CD41 vs. Down p=0.194, Gr1 vs. Down 1124 
p=5.39e-28 ; CEBP: FL vs. Down p=1.12e-3, CD41 vs. Down p=1.49e-22, Gr1 vs. Down p=2.5e-1125 
201 1126 





Figure 6.  1130 
GATA and CEBPA activities functionally controls EG-induced phenotypes. 1131 
A, Quantitative RT-PCR analyses in LIN- CTRL and iEG FL14.5 and ABM-derived cells after 1132 
24h in liquid culture with Dox. Mean+/-SEM (n=3) is shown. 1133 
B, Quantitative RT-PCR analyses in CTRL and iEG ABM LT-HSC and MPP4-derived cells at 1134 
P1. Mean+/-SEM (n=3) is shown. 1135 
C, Experimental design to ectopically express indicated TF in iEG ABM LT-HSC and MPP4. 1136 
D, Representative flow cytometry analyses of cells obtained at P1 after transduction of WT 1137 
and iEG MPP4 with ERG, GATA1 or GFP-only retroviruses. Analysis was gated on GFP+ cells. 1138 
E, Representative flow cytometry analyses of cells obtained at P1 after transduction of WT and 1139 
iEG LT-HSC with SPI1, CEBPA or GFP-only retroviruses. Analysis was gated on GFP+ cells. 1140 
F, Quantitative RT-PCR analyses in blasts from patients with AMKL (n=8, EG- AMKL: empty 1141 
circles, EG+ AMKL: orange circles), AML (n=7, EG- AMKL: empty squares, EG+ AMKL: blue 1142 
squares) and in the different blast populations from the dual phenotype ETO2-GLIS2+ AML 1143 
patient (#5) presented in Figure 1H (CD41-CD15- immature: black triangle, CD41+CD15- 1144 
megakaryoblastic: orange triangle, CD41-CD15+ myeloid: blue triangle). Statistical significance 1145 
is indicated as p values (Mann-Whitney test). *: p<0.05, **: p<0.01, ***: p<0.001. 1146 
G, Schematic representation of the bases for the pediatric and phenotypic specificities 1147 
associated with ETO2-GLIS2 leukemia. Our data and published studies (22,26,23,24) support 1148 
the idea that a shift from a higher megakaryoblastic potential (orange color) to a higher myeloid 1149 
potential (blue color) in fetal vs. adult hematopoiesis is associated with a change in the GATA1 1150 
vs. CEBPA activities. Here we show that ETO2-GLIS2 imposes a stronger deregulation of self-1151 
renewal programs in fetal compared to adult hematopoiesis (including higher ERG and lower 1152 
SPI1 activities). The combination of the basal transcriptional state controlling phenotypic 1153 
output with a differential effect of ETO2-GLIS2 on self-renewal programs during hematopoietic 1154 
ontogeny may therefore underlies the strong prevalence of acute megakaryoblastic leukemia 1155 
(AMKL) in early childhood and more generally represent a basis for the specific pediatric and 1156 
phenotypic incidence of human AMKL vs. other myeloid leukemia (AML) (lower part). 1157 
Statistical significance is indicated as p values (Student’s t test) except otherwise mentioned. 1158 
*: p<0.05, **: p<0.01, ***: p<0.001. 1159 
 1160 
 1161 
Figure 7.  1162 
ETO2-GLIS2 reversibly transforms LT-HSC.  1163 
A, Experimental design: purified LT-HSC and MPP cells from wild type (WT) or iEG mice 1164 
expressing the Ubiquitin-GFP (GFP+) were transplanted into wild-type Dox-treated recipients. 1165 
Note that GFP expression is not Dox-dependent and therefore engraftment of all cells can be 1166 
followed using GFP regardless of the Dox treatment.  1167 
B, Kaplan-Meier survival curve of recipients of naive iEG LT-HSC from ABM or FL, on Dox. 1168 
Recipients were treated with Dox after transplantation. Log rank Mantel-Cox test iEG HSC FL 1169 
vs. ABM recipients: p=0.0171. Median survival HSC ABM: 312d, HSC FL : 27d. 1170 
C, Kaplan-Meier survival plot of recipients of naive iEG MPP3 from ABM or FL kept on Dox. 1171 
Log rank Mantel-Cox test iEG MPP3 FL vs. ABM recipients: p=0.0010. Median survival MPP3 1172 
FL: 33d. 1173 
D, Percentages of GFP+ cells in BM, spleen weights, white blood cell (WBC) counts and 1174 
platelet counts (Plt) in CTRL and iEG ABM HSC recipients and iEG FL HSC and MPP3 1175 
recipients. Spleen (CTRL vs. FL: p<0.0001, CTRL vs. ABM: p=0.0039), WBC (CTRL vs. FL: 1176 
p=0.0095, CTRL vs. ABM: p=0.0309), Plt (CTRL vs. FL: p=0.0079, CTRL vs. ABM: p=0.1536).  1177 
E, Representative flow cytometry analysis of diseased recipients at time of sacrifice.  1178 
F, Histogram of the percentages of CD41+ and CD11b+Gr1+ cells in the BM of primary diseased 1179 
recipients. CD41+ (CTRL vs. FL: p<0.0001, CTRL vs. ABM: p=0.0005), CD11b+Gr1+ (CTRL 1180 
vs. FL: p=0.0016, CTRL vs. ABM: p=0.0717).  1181 
 
 28 
G, Histogram of the percentages of B220+, CD4+ and CD8+ cells in the spleen of primary 1182 
diseased recipients. B220+ (CTRL vs. FL: p=0.012, CTRL vs. ABM: p=0.0102), T cells=CD4+ 1183 
or CD8+ cells (CTRL vs. FL: p<0.0001, CTRL vs. ABM: p=0.0016).  1184 
H, Experimental design: 1x106 BM cells from the diseased primary recipients at time of analysis 1185 
were transplanted into secondary sub-lethally irradiated Dox-treated recipients. After two 1186 
weeks, Dox treatment was maintained for group A (GFP+ cells expressing iEG) and ceased in 1187 
group B (GFP+ cells lacking iEG expression).  1188 
I, Plt and RBC counts (top panels) and respective percentages of GFP+ cells (lower panels) in 1189 
secondary recipients of ABM LT-HSC-derived disease. D0: time at which Dox was maintained 1190 
in group A and withdrawn in group B. Mean+/-SEM (n=6 / group) is shown.  1191 
J, Kaplan-Meier survival plot of secondary recipients transplanted with cells from diseased 1192 
primary iEG ABM LT-HSC recipients. Secondary recipients were kept on Dox (Dox+) or not 1193 
(Dox-). Log rank Mantel-Cox test Dox- vs. Dox+ recipients: p=0.0086. 1194 
K, Flow cytometry analyses in secondary recipients of iEG ABM LT-HSC-derived disease at 1195 
six months after Dox withdrawal. Analyses were gated on GFP+ (iEG donor-derived) or GFP- 1196 
(WT recipient) cells. 1197 
Statistical significance is indicated as p values (Student’s t test except when otherwise 1198 
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